{"product_id":"pcas-pestle-analysis","title":"PCAS PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our expert PESTLE Analysis of PCAS—uncover how political, economic, social, technological, legal, and environmental forces are shaping its trajectory and your opportunity set; purchase the full report to access actionable insights, ready-to-use charts, and strategic recommendations for investors, consultants, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU Strategic Autonomy Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe EU has pledged over €10bn (2024–2027) for strategic autonomy in health, pushing reshoring of essential medicine production from Asia; this reduces supply-chain risk and favors European API makers like PCAS. Political backing and national subsidies (e.g., France\/Germany grant schemes covering up to 30% capex) improve project IRRs and de-risk expansion investments for PCAS. Increased public procurement and pharma sovereignty targets imply a predictable multi-year revenue pipeline for EU contract manufacturers, supporting capacity utilization and pricing stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing and Healthcare Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment pressure to curb healthcare spending in Europe and North America—e.g., UK NHS cost-controls and US drug pricing debates reducing list prices by up to 10–20% in some classes in 2024—compresses pharma margins and drives clients to outsource for cost savings, boosting PCAS's bargaining leverage but pushing tougher contract terms; simultaneous shifts in reimbursement (e.g., 2024 CMS oncology value-based pilots covering gene therapies) redirect R\u0026amp;D toward high-value, reimbursable assets, altering service demand mix for PCAS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions and evolving tariffs between major blocs raised EU import duties on certain chemical intermediates by up to 5-10% in 2024, increasing PCAS input costs and compressing margins for specialty chemicals producers.\u003c\/p\u003e\n\u003cp\u003ePCAS must navigate complex dual-use regulations and customs controls—EU Regulation 2021\/821 and stricter 2023 precursor monitoring—adding compliance costs that can increase lead times by 7-12% per shipment.\u003c\/p\u003e\n\u003cp\u003ePolitical stability in France and the Eurozone is pivotal: France accounted for ~18% of PCAS revenue in 2024, so any disruption to transport or energy supplies could materially affect operations and supply-chain continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Support for Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe French Research Tax Credit (CIR) and Innovation Tax Credit (CII) reduce R\u0026amp;D costs; CIR reimbursed up to 30% for first €100k and 5% thereafter, delivering PCAS estimated savings of €4–8m annually on R\u0026amp;D and pilot-scale projects (2024 figures).\u003c\/p\u003e\n\u003cp\u003ePCAS leverages grants from Bpifrance and EU Horizon, funding ~15–25% of select projects; any reduction in these incentives would materially constrain capital allocation to novel synthesis platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CIR: up to 30% (first €100k); PCAS R\u0026amp;D savings €4–8m\/year\u003c\/li\u003e\n\u003cli\u003eGrant support: Bpifrance\/Horizon covering 15–25% of project costs\u003c\/li\u003e\n\u003cli\u003ePolicy cuts could reduce new-tech investment capacity materially\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical moves toward EMA-FDA harmonization—such as ICH updates and the FDA's 2024 guidance convergence initiatives—lower barriers for PCAS, enabling CDMO revenue expansion into EU\/US markets; global CDMO market grew 7.2% to about $74.8B in 2024, boosting PCAS addressable market.\u003c\/p\u003e\n\u003cp\u003eConsistent frameworks cut compliance costs and administrative workload for multi-market approvals, improving time-to-market and margin retention for PCAS contracts.\u003c\/p\u003e\n\u003cp\u003eYet rising protectionist measures in 2024–25 tariffs and localized manufacturing incentives risk fragmenting standards and could raise cross-border compliance costs for PCAS.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEMA-FDA alignment ongoing (ICH updates, 2024 guidance)\u003c\/li\u003e\n\u003cli\u003eGlobal CDMO market ≈ $74.8B in 2024 (+7.2%)\u003c\/li\u003e\n\u003cli\u003eHarmonization reduces multi-market compliance costs\u003c\/li\u003e\n\u003cli\u003eProtectionism (2024–25) could disrupt agreements and raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU funds + grants de-risk reshoring; tariffs, cuts pressure margins but boost outsourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong EU funding (€10bn 2024–27) and national capex grants (up to 30%) de-risk reshoring, supporting PCAS revenue visibility; UK\/US cost-controls cut pharma margins (price cuts 10–20% in 2024) but drive outsourcing; trade\/tariff increases (EU duties +5–10% 2024) and tighter dual-use rules raise input\/compliance costs; CIR\/CII and Bpifrance\/Horizon grants (15–25% project funding) offset R\u0026amp;D spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU strategic fund\u003c\/td\u003e\n\u003ctd\u003e€10bn (2024–27)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal CDMO market\u003c\/td\u003e\n\u003ctd\u003e$74.8B (+7.2%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU duties on intermediates\u003c\/td\u003e\n\u003ctd\u003e+5–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCIR savings\u003c\/td\u003e\n\u003ctd\u003e€4–8m\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect PCAS across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to inform strategy, risk mitigation, and opportunity identification for executives, investors, and consultants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses the full PCAS PESTLE into a clear, shareable summary segmented by factors for quick reference in meetings or presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy Market Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a chemical manufacturer, PCAS faces sharp sensitivity to European electricity and natural gas prices—European power baseload averages rose ~18% in 2023 vs 2022 and TTF gas front-month volatility reached \u0026gt;60% in 2022–2023, threatening margins unless passed through via indexed contracts; pass-through rates and contract coverage levels determine impact. Transitioning to renewables and on-site generation (solar\/wind + 2024 battery cost declines ~20% vs 2020) is a priority to stabilize input costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCDMO Market Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CDMO sector saw ~35 M\u0026amp;A transactions in 2024 with global deal value ~USD 24bn, driving consolidation as large players buy niche specialists; PCAS must emphasize technical differentiation in complex chemistries to compete in a market where top 10 firms now hold an estimated 48% share. Market valuations and abundant private capital—dry powder in life sciences funds ~USD 160bn in 2025—shape PCAS growth options between organic expansion and acquisition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rates and Capital Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe cost of borrowing is crucial for PCAS, which needs heavy capital for specialized manufacturing; a 2024 global average corporate borrowing rate near 6.5% increased capital costs and pressured capex timing. High rates through 2024–mid‑2025 slowed expansion of production lines and deferred upgrades, shrinking projected capex by an estimated 10–15% versus pre‑rate forecasts. By late 2025, policy rate stabilisation—US Fed funds around 5.25%–5.50%—improves long‑term debt prospects, lowering weighted average cost of capital and enabling strategic financing for multi‑year projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePCAS bills mainly in EUR but invoices many international contracts in USD; a 2024 EUR\/USD move from 1.08 to 1.06 would cut USD-denominated revenue by ~1.85% when converted, affecting margins and price competitiveness.\u003c\/p\u003e\n\u003cp\u003eHedging using forwards\/options is essential—ECB data shows corporates increased FX forward usage by 12% in 2024—reducing reported EUR revenue volatility and protecting quoted USD prices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEUR base, USD invoices; 2024 EUR\/USD range ~1.06–1.10\u003c\/li\u003e\n\u003cli\u003e1.85% revenue swing per 0.02 EUR\/USD move at $1m invoiced\u003c\/li\u003e\n\u003cli\u003eHedging adoption +12% (2024 ECB corporate FX data)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Specialized Labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rising cost of living has pushed wage demands for specialized chemical engineers and researchers up by an estimated 6–8% in 2024 across Western Europe, pressuring PCAS to enhance compensation to retain talent while containing operating margins.\u003c\/p\u003e\n\u003cp\u003eBalancing competitive packages amid 2024 labor cost inflation—wage growth in EU advanced markets outpacing emerging markets by ~3–5 percentage points—raises COGS and EBITDA pressure for PCAS versus lower-cost competitors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 Western Europe skilled wage growth: ~6–8%\u003c\/li\u003e\n\u003cli\u003eGap vs emerging markets: ~3–5 percentage points\u003c\/li\u003e\n\u003cli\u003eImpact: upward pressure on COGS and downward on EBITDA margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising energy costs, volatile FX and consolidation lift input-cost and financing risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnergy price volatility (power +18% in 2023; TTF gas vol \u0026gt;60% in 2022–23) and renewables capex declines (~20% vs 2020) drive input-cost risk and mitigation. CDMO consolidation: ~35 M\u0026amp;A in 2024, ~$24bn value; top 10 ≈48% share. Borrowing costs raised WACC (global avg corporate rate ~6.5% in 2024). FX: EUR\/USD 2024 range 1.06–1.10; 0.02 move ≈1.85% revenue swing. Western EU skilled wage growth ~6–8% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePower change\u003c\/td\u003e\n\u003ctd\u003e+18% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTF vol\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e~35 deals; $24bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorp rate\u003c\/td\u003e\n\u003ctd\u003e~6.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/USD\u003c\/td\u003e\n\u003ctd\u003e1.06–1.10 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWage growth\u003c\/td\u003e\n\u003ctd\u003e6–8% (W. EU, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003ePCAS PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PCAS PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751977169273,"sku":"pcas-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/pcas-pestle-analysis.png?v=1772236622","url":"https:\/\/growthsharematrix.com\/products\/pcas-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}